Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2025 investor letter. A ...

Haemonetics (NYSE: HAE) announced today that it acquired percutaneous vessel closure device maker Vivasure Medical.

Haemonetics will shell out up to 185 million euros ($216 million) to acquire Vivasure Medical, a Galway, Ireland-based medtech that makes arterial closure devices.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

Why Haemonetics’ Price Target Just Nudged Higher Haemonetics’ fair value estimate has been nudged higher from about US$90.20 ...

Investors may be wondering whether Haemonetics at around US$74 is offering value right now, or whether the market is still undecided about its future potential. The stock has been quite mixed lately, ...

The ELITE arterial study demonstrated ease of use for Vivasure's PerQseal Elite with no need for pre-close.

Analysts have recently evaluated Haemonetics and provided 12-month price targets. The average target is $87.45, accompanied ...

Orchestra BioMed (Nasdaq:OBIO) expects to receive up to $21 million in cash as a result of Haemonetics' recent.

BOSTON, March 2, 2021 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $435,000,000 aggregate principal amount of 0.00% Convertible ...

BOSTON, Oct. 6, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2022 financial results at 6:00 am EST on Tuesday, ...